Where Will Elan Go Next?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

With shares of Elan (NYSE:ELN) trading around $15, is ELN an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Elan is a biotechnology company that is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Such diseases include Alzheimer’s Disease, Parkinson’s Disease, Celiac disease, Crohn’s Disease, and Narcolepsy. As these diseases take a toll on many lives, any positive progress Elan can make will be very rewarding. As many of these diseases come to the attention of people around the world, biotechnology companies such as Elan will see rising demand.

Just recently, it was announced that Perrigo (NASDAQ:PRGO) will purchase the Irish pharmaceutical company, Elan, for $8.6 billion in order to take advantage of Ireland’s lower tax rates. Perrigo’s corporate income tax rate will drop from 30 percent to 12.5 percent by re-domiciling in Ireland. According to Perrigo, the deal will save the company $150 million a year in taxes.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business